GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reiterated by investment analysts at Panmure Gordon in a note issued to investors on Wednesday, Analyst Ratings Network.com reports. They currently have a GBX 1,750 ($28.73) price objective on the stock. Panmure Gordon’s price objective would indicate a potential upside of 5.33% from the stock’s previous close.
GlaxoSmithKline (LON:GSK) opened at 1659.4999 on Wednesday. GlaxoSmithKline has a 52 week low of GBX 1398.00 and a 52 week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1599. and a 200-day moving average of GBX 1629.. The company’s market cap is £79.938 billion.
GSK has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Thursday, January 16th. They now have a GBX 1,500 ($24.62) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, January 14th. They now have a GBX 1,750 ($28.73) price target on the stock. Finally, analysts at UBS AG initiated coverage on shares of GlaxoSmithKline in a research note to investors on Friday, January 10th. They set a “neutral” rating on the stock. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of GBX 1,618.66 ($26.57).
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.